Google
Trusted Resources: News & Events
Latest announcements and gatherings
Big Jump in Success for Sickle Cell Transplants
Doubling the dose of total-body irradiation (TBI) led to a near-doubling of the engraftment rate for patients with severe hemoglobinopathies undergoing haploidentical transplants, a small clinical trial showed.
All but one of 17 patients had successful engraftment after receiving 400 cGy TBI as part of a nonmyeloablative conditioning regimen. Following successful engraftment, 15 of 16 patients remained transfusion independent, and 14 of 16 discontinued immunosuppression.
Four patients developed grade 2 acute graft-versus-host disease (GVHD) and one developed grade 3, but GVHD had resolved in all cases at the most recent follow-up, Javier Bolaños-Meade, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, and co-authors reported online in The Lancet Haematology.
+myBinderRelated Content
-
Comparative Cost Analysis of Therapy in Sickle Cell Anemia: Supportive Care Vs. Bone Marrow TransplantObjective: A comparative cost analysis o...
-
MARAC Statement: Health Insurance Coverage for Hematopoietic Stem Cell Transplant for Sickle Cell Disease from HLA-m...Hematopoietic stem cell transplant for s...
-
Isaac Singleton: Sickle Cell Freehttps://www.youtube.com/watch?v=a5mMgnuz...
-
Today’s Faces of Sickle Cell Disease: John Tisdale, MDFor many years, John Tisdale has been wo...
-
Family Celebrates 7-Year-Old’s Sickle Cell Cure Thanks to Sister’s Life-Saving GiftOne 7-year-old who suffered his whole li...
-
Health disparity in hematopoietic cell transplantation for sickle cell disease: Analyzing the association of insuran...The impact of racial and socioeconomic s...
-
Sisterly bond behind sickle-cell curehttps://www.youtube.com/watch?v=9S-xVGsR...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.